|Awarded On||February 18, 2015|
|Title||Development of Rhenium Nanoliposomes for Cancer Therapy|
|Program||Product Development Research|
|Award Mechanism||New Company Product Development Award|
|Principal Investigator/Program Director||Andrew Brenner|
|Cancer Sites||Brain and Other Nervous System|
Radiation therapy remains an essential component of treatment for most cancers, including primary brain tumors. Theoretically, any tumor can be controlled if a sufficient dose of radiation is delivered. The main limiting factor is the potential for damage to the surrounding normal body. This is especially true with brain tumors, as damage to the surrounding normal brain can result in profound side effects.
We have developed a method of loading radiation molecules into fatty particles about one thousandth the size of a cell, termed nanoliposomes or RNL. This can be injected into a tumor where it is essentially ‘ingested’ by the tumor cells, and the tumor is irradiated from the inside out. Due...